ÜBER UNS

Zielstrukturen als neuartiger Wirkmechanismus für Arzneimittel (ProxiDrugs)

Die neue Substanzklasse der proximity- (durch Nähe) induzierten Wirkstoffe erlaubt den gezielten Abbau von krankheitsrelevanten Proteinen (Zielstrukturen) und eröffnet damit Therapieoptionen bei vielen Erkrankungen, u.a. solchen mit nicht ausreichend gedecktem Bedarf („unmet medical need“). Das Prinzip besteht darin, dass die Zielstrukturen durch die kleinen, meist bifunktionalen Wirkstoffe direkt dem zelleigenen Abfallsystem zugeführt werden. Es wird davon ausgegangen, dass ca. 80% der bisher als „undruggable“ geltenden Proteine so therapeutisch zugänglich gemacht werden können. Im Rhein-MainGebiet ist in europaweit einzigartiger Weise die benötigte Expertise vorhanden, um dieser innovativen Strategie zur breiten Anwendung zu verhelfen. Die Goethe-Universität Frankfurt plant daher gemeinsam mit dem Fraunhofer-Institut IME und der Technischen Universität Darmstadt die Etablierung des Zukunftsclusters ProxiDrugs. Kernstück des Clusters ist eine Technologieplattform als Basis für „Drug Discovery“ und präklinische Entwicklung. Der Cluster plant, die neue Substanzklasse in allen maßgeblichen Bereichen weiter zu entwickeln: Die Strategie umfasst die Identifikation geeigneter Funktionseinheiten zur Erzeugung der Wirkstoffe, die gezielte Optimierung pharmakologischer Eigenschaften und den Transfer in die ersten klinischen Phasen. Der Cluster wird insbesondere vom Knowhow des Frankfurter Standortes des Structural Genomics Consortiums und des Fraunhofer IME, den dortigen relevanten Einrichtungen und Geräten und den vorhandenen Screening-Bibliotheken profitieren. Zahlreiche regionale Partner haben bereits ihr Interesse an konkreten Projekten bekundet, darunter große Pharmafirmen und kleinere Ausgründungen.

Kontaktieren Sie uns.

NEWS

03 Feb 2021 - PROXIDRUGS successful in Clusters4Future competition

news image

As announced today, the PROXIDRUGS consortium has been selected for funding within the Clusters4Future initiative of the Federal Ministry of Education and Research (BMBF), which aims at promoting regional innovation networks for the benefit of economy and society. PROXIDRUGS will be funded with up to 15 M € for the next three years, as only one of 7 clusters selected for funding from a total of 137 applications. 

The consortium concentrates on developing new treatments for diseases with high unmet medical need by utilizing the new concept of proximity induction in drug design. It is assumed that 80% of the proteins that are so far deemed as undruggable may be targeted by this strategy. “Proxidrugs open up exciting new therapeutic options in numerous diseases including cancer, neurodegeneration and infection. Proxidrugs can trigger degradation of disease-relevant proteins in a highly specific fashion by directing them towards the cellular recycling system”, explains cluster speaker Ivan Đikić from Goethe University. 

PROXIDRUGS has been set up as a regional network of partners from academia and industry, covering the entire value chain from basic to translational research. Academic participants are based at Goethe University Frankfurt, TU Darmstadt, University of Heidelberg, the MPI of Biophysics and the Fraunhofer Institute for Translational Medicine and Pharmacology, and they are closely working together with major pharma partners. 

At Goethe University, the Frankfurt Center for Innovation & Technologies will be established as academic innovation hub that provides the needed technologies to the consortium. Ivan Đikić adds: “The early and close collaboration between all partners marks the start of a new era in drug development within the Rhine Main region. This culture of teamwork and sharing knowledge paves the way for an efficient transfer towards therapeutic applications.”
 

VERANSTALTUNGEN

»Identifying fragments binding to the entire genome and proteome of SARS-CoV-2«
Joint Lecture PROXIDRUGS & ENABLE
speakerimage
Prof. Dr. Harald Schwalbe
Institute for Organic Chemistry and Chemical Biology
Center for Biomolecular Magnetic Resonance (BMRZ)
Johann Wolfgang Goethe-University Frankfurt

27. Oct 2021 16:00h

Location: UKF, Building 23, auditorium 23-3

Hybrid Lecture

»Multidisciplinary approaches in development of targeted protein degraders«
PROXIDRUGS Lecture Series
speakerimage
Radoslaw Nowak
Dana-Farber Cancer Institute, Harvard Medical School

14. Sep 2021 17:00h

Location: Virtual Meeting

Virtual Lecture

»The Coming of Age of De Novo Protein Design«
TU Darmstadt Chemistry Seminar Series
speakerimage
Prof. Dr. David Baker
Washington University, Seattle

22. Jun 2021 17:00h

Location: Virtual Meeting

Virtual Lecture


Download

»Mapping the Degradable Kinome Provides a Resource for Drug Discovery«
PROXIDRUGS Lecture Series
speakerimage
Fleur M. Ferguson
University of California San Diego,
La Jolla,
US

01. Jun 2021 17:00h

Location: Virtual Lecture via Zoom

Virtual Lecture


Download Announcement
»Rapid response technologies for protein manufacturing and drug discovery«
TU Darmstadt Chemistry Seminar Series
speakerimage
Prof. Dr. Bradley Pentelute
Massachusetts Institute of Technology Boston

25. May 2021 15:00h

Location: to be announced

Virtual Lecture

»Large-Scale Chemoproteomic Profiling Surveys the Degradable Proteome for Accelerated Degrader Development«
PROXIDRUGS Lecture Series
speakerimage
Katherine A. Donovan
Dana-Farber Cancer Institute & Harvard Medical School,
Boston,
US

18. May 2021 16:00h

Location: Virtual Lecture via Zoom

Virtual Lecture


Download Announcement
»Regulation of Histone Methylation with Methyl-Lysine Reader Targeted Degraders«
PROXIDRUGS Lecture Series
speakerimage
Lindsey Ingerman James
University of North Carolina,
Chapel Hill,
US

31. Mar 2021 16:00h

Location: Virtual Lecture via Zoom

Virtual Lecture


Download Announcement
»Lessons from thalidomide analogues as prototype molecular glue degraders«
PROXIDRUGS Lecture Series
speakerimage
Philip Chamberlain
Neomorph, Inc.

16. Feb 2021 17:00h

Location: Virtual Lecture via Zoom

Virtual Lecture


Download Announcement
»Reimagining Druggability using Chemoproteomic Platforms«
PROXIDRUGS Lecture Series
speakerimage
Daniel K. Nomura
University of California,
Berkeley,
US

16. Nov 2020 17:00h

Location: Virtual Lecture via Zoom

Virtual Lecture


Download Announcement
»Molecular Mechanisms of Small Molecule Mediated Ubiquitin Ligase Targeting«
PROXIDRUGS Lecture Series
speakerimage
Eric Fischer
Dana-Farber Cancer Institute & Harvard Medical School,
Boston,
US

27. Oct 2020 16:30h

Location: Virtual Lecture via Zoom

Virtual Lecture


Download Announcement
»Probing Gene Control via Targeted Protein Degradation«
PROXIDRUGS Lecture Series
speakerimage
Georg Winter
Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM),
Vienna,
AT

29. Sep 2020 16:00h

Location: Virtual Lecture via Zoom; Meeting-ID: 962 0881 2086 Kenncode: 612251

Virtual Lecture


Download Announcement
»Manipulating developmental pathways using proximity-inducing antibody modalities«
PROXIDRUGS Lecture Series
speakerimage
Stephane Angers
Leslie Dan Faculty of Pharmacy,
University of Toronto,
CA

01. Sep 2020 16:00h

Location: Virtual Lecture via Zoom

Virtual Lecture


Download Announcement
»Multispecific drugs, induced proximity, and the future of biopharmaceutical innovation«
PROXIDRUGS Lecture Series
speakerimage
Ray Deshaies
Senior Vice President,
Global Research,
AMGEN,
USA

25. Aug 2020 17:00h

Location: Virtual Lecture via Zoom

Virtual Lecture


Download Announcement

A BMBF Zukunftscluster Candidate
FKZ: 03ZK109AA